BMO Expands Canadian Depositary Receipt Lineup with 10 New Listings from Europe and Japan

BMO's CDRs offer enhanced portfolio diversification opportunities for Canadian investors enabling them to hold shares in international companies that trade on a Canadian exchange in Canadian dollars

Bank of Montreal (BMO) announced 10 new CDRs will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.

BMO's new CDRs will trade under the following tickers:

Company Name

CDR Ticker

Jurisdiction

Novo Nordisk A/S

NOVE

Denmark

SAP SE

SAPG

Germany

ASML Holding NV

ASMH

Netherlands

CIE Financiere Richemont AG

RCHM

Switzerland

Novartis AG

NOVN

Switzerland

Roche Holdings AG

ROCH

Switzerland

UBS Group AG

UBS

Switzerland

Mitsubishi Corp.

MTSU

Japan

Mitsubishi UFJ Financial Group

MUFG

Japan

Softbank Group Corp.

SFTB

Japan

For more information on BMO's CDRs, please visit www.bmocdrs.com .

This material is for information purposes only. The information contained herein is not, and should not be construed as, investment, tax or legal advice to any party.

An investment in CDRs issued by BMO may not be suitable for all investors. Important information about these investment products is contained in the short form base shelf prospectus and prospectus supplement for each series of CDRs (together, the " Prospectus "). Purchasers are directed to www.sedarplus.ca or to www.bmogam.com to obtain copies of the Prospectus and related disclosure before purchasing CDRs of a particular series. The information contained herein is not a recommendation to purchase these investment products.

Each series of CDRs relates to a single class of equity securities (the " Underlying Shares ") of an issuer incorporated outside of Canada (the " Underlying Issuer "). For each series of CDRs, the Prospectus will provide additional information regarding such series, including information regarding the Underlying Issuer and Underlying Shares for such series. Neither BMO and its affiliates nor any other person involved in the distribution of CDRs accepts any responsibility for any disclosure provided by any Underlying Issuer (including information contained herein or in the Prospectus that has been extracted from any Underlying Issuer's publicly disseminated disclosure). Each series of CDRs is only offered to investors in Canada in accordance with applicable laws and regulatory requirements.

"BMO (M-bar roundel symbol)" is a registered trademark of Bank of Montreal , used under licence.

About BMO Financial Group

BMO Financial Group is the eighth largest bank in North America by assets, with total assets of $1.41 trillion as of October 31, 2024. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States , and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life , BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society.

SOURCE BMO Financial Group

News Provided by PR Newswire via QuoteMedia

NVS
The Conversation (0)
Troy Minerals (CSE:TROY)

Troy Minerals Reports Drilling Results from the Lake Owen Project, Wyoming. Critical Minerals inclusive of Scandium (Rare Earths Element) Discovered

Troy Minerals Inc. ("Troy" or the "Company") (CSE:TROY)(OTCQB:TROYF)(FSE:VJ3) is pleased to announce that its two-hole maiden drilling program at Lake Owen Project has been completed and assays of the first pass of selective sampling have been received. The 100% owned Lake Owen Project (the "Project") is located 50 km southwest of Laramie, Wyoming, USA (see Figures 1,2).

The Project is a Proterozoic layered mafic intrusion complex with a long history of sporadic exploration primarily for Platinum Group Elements. Similar in style to the Stillwater Complex in USA and the Merensky Reef of South Africa, the Lake Owen Complex is a highly prospective North American based target with a strong potential for significant vanadium, titanium, PGE and associated metals mineralization.

Keep reading...Show less
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less

Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

  • Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment
  • Made Significant Progress Strengthening the R&D Organization
  • On Track to Exceed Net Cost Savings Targets

Pfizer Inc. (NYSE: PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance (1) .

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

  • Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) regimen compared to SOC alone
  • Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in more than 30 years
  • Results have been shared with global health authorities to support potential regulatory filings

Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a clinically meaningful and statistically significant improvement with sasanlimab in combination with BCG (induction and maintenance) as compared to BCG alone (induction and maintenance): Hazard Ratio (HR) of 0.68; 95% Confidence Interval (CI), 0.49-0.94; 2-sided p=0.019; median EFS not yet reached. These findings show a 32% reduction in risk of disease-related events, including high-grade disease recurrence or progression, with the sasanlimab combination regimen as compared with SOC treatment alone. Pre-specified subgroup analyses for patients harboring higher risk disease showed consistent benefit with EFS HR of 0.63 (0.41, 0.96) for T1 disease, and EFS HR 0.53 (0.29, 0.98) for those with CIS disease.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Pfizer Declares Second-Quarter 2025 Dividend

Board of Directors approves quarterly cash dividend of $0.43 per share

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO® to Include Adults Aged 50 to 59 at Increased Risk of Disease

  • Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of respiratory syncytial virus (RSV) vaccines approved for adults 50-59 years of age at increased risk of RSV-associated lower respiratory tract disease (LRTD). This includes ABRYSVO ® (Respiratory Syncytial Virus Vaccine), which in October 2024, the U.S. Food and Drug Administration approved for the prevention of RSV-associated LRTD in adults aged 18 to 59 at increased risk of severe disease.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×